SCHEMBL17664616

SCHEMBL17664616

CCSc1cc(C(F)(F)F)ccc1-c1cc(OC)ncn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
KDR P35968 1/20 0.35
MAPK14 Q16539 1/20 0.35
TNNI3K Q59H18 1/20 0.35
TSHR P16473 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
DDR1 Q08345 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18908785 0.84 LMNA (0.39) PTGDR2KDRCYP1A2KDM4ELMNA
SCHEMBL19501576 0.81 PTGDR2 (0.40) PTGDR2TSHRCYP1A2DDR1ALOX5AP
SCHEMBL17664492 0.79 FEN1 (0.46) SCN9AKDRMAPK14TNNI3KALOX5AP
SCHEMBL17664477 0.77 SCN9A (0.41) SCN9APTGDR2KDRMAPK14TNNI3K
SCHEMBL17664494 0.76 CRHR1 (0.39) SCN9APTGDR2CYP1A2DDR1CRHR1
SCHEMBL18843178 0.75 DDR1 (0.38) PTGDR2CYP1A2MAPK1DDR1CRHR1
SCHEMBL22809140 0.74 GABRG2 (0.46) CYP2C19CYP1A2KDM4ELMNAMAPK1
Methane SCHEMBL23369618 0.74 DDR1 (0.37) PTGDR2CYP1A2MAPK1DDR1CRHR1
SCHEMBL18785056 0.73 ALOX5AP (0.39) PTGDR2CYP1A2KDM4EDDR1ALOX5AP
SCHEMBL28074599 0.73 TSHR (0.43) KDRMAPK14TNNI3KTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3202762-B1 PYRIMIDINONE COMPOUND SUMITOMO CHEMICAL CO (JP) 2019-06-19 EP disclosed
US-9802930-B1 Pyrimidinone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20170305896-A1 PYRIMIDINONE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
EP-3202762-A1 PYRIMIDINONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2017-08-09 EP disclosed
WO-2017090654-A1 PEST CONTROL COMPOSITION AND USE THEREOF 住友化学株式会社 2017-06-01 WO disclosed
WO-2016052247-A1 PYRIMIDINONE COMPOUND 住友化学株式会社 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305896-A1 PYRIMIDINONE COMPOUND C5, C3AR1, CCR3 SCN9A 2811/4885PTGDR2 1449/4885KDR 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.